Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · IEX Real-Time Price · USD
0.345
-0.003 (-0.72%)
At close: Jul 19, 2024, 4:00 PM
0.339
-0.005 (-1.51%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Cara Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cara Therapeutics stock have an average target of 1.00, which predicts an increase of 190.28% from the current stock price of 0.34.
Analyst Consensus: Hold
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for CARA stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 2 | 0 |
Buy | 1 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 4 | 4 |
Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 7 | 7 | 6 | 6 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $10 → $1 | Strong Buy → Hold | Downgrades | $10 → $1 | +190.28% | Jun 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +1,351.38% | May 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.6 | Strong Buy | Reiterates | $3.6 | +944.99% | May 15, 2024 |
Financial Forecast
Revenue This Year
6.54M
from 20.97M
Decreased by -68.80%
Revenue Next Year
6.93M
from 6.54M
Increased by 5.93%
EPS This Year
-1.30
from -2.19
EPS Next Year
-0.83
from -1.30
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 10.4M | 13.2M | 17.4M | 27.8M | 86.3M |
Avg | 6.5M | 6.9M | 7.2M | 19.8M | 65.5M |
Low | 4.7M | 3.1M | 1.5M | 12.4M | 29.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -50.2% | 101.5% | 150.9% | 288.5% | 335.9% |
Avg | -68.8% | 5.9% | 3.3% | 176.3% | 231.0% |
Low | -77.6% | -53.2% | -78.8% | 73.8% | 49.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.18 | -0.36 | -0.34 | -0.33 | -0.03 |
Avg | -1.30 | -0.83 | -0.76 | -0.83 | -0.64 |
Low | -1.35 | -1.11 | -1.20 | -1.10 | -1.14 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.